Controversial nods came for Urogen’s Zusduri and Astra/Daiichi’s Datroway.
ApexOnco Front Page
Recent articles
Adverse events will be closely watched when full data are reported.
Summit gatecrashes ASCO, but Harmoni shows no OS benefit and a large patient overlap.
The second line shows no respite for Merck & Co's ROR1-targeting ADC.
The Breakwater study hits on overall survival with "unprecedented" data.
The combined company's MALT1 inhibitor has started phase 1.
Crunch time approaches for UroGen.
Meanwhile, Pfizer reckons it's found the right dose for its KAT6.
